ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,040.04
1.10%
Dow Jones
43,297.03
0.91%
US Dollar vs MXN
20.1644
-0.02%
Brent Oil
73.285
0.00%
Bitcoin
97,874.33
-0.82%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Carisma Therapeutics Inc (CARM) Cotización

Carisma Therapeutics Inc

Carisma Therapeutics Inc (CARM)

Carmanah Minerals Corp
Carrefour Property Development
0.399
0.011
(2.84%)
Cerrado 24 Diciembre 3:00PM
Delayed by 15 minutes
0.399
0.00
(0.00%)
Fuera de horario: 3:00PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
0.399
Postura de Compra
0.3989
Postura de Venta
0.399
Volume Operado de la Acción
439,958
0.38 Rango del Día 0.4075
0.3809 Rango de 52 semanas 3.16
Capitalización de Mercado [m]
16.658M
Precio Anterior
0.388
Precio de Apertura
0.38
Hora
4460
@
0.3989
(formt)
Última hora de negociación
Volumen financiero
US$ 171,321
Precio Promedio Ponderado
0.389403
Volumen promedio (3 m)
213,348
Acciones en circulación
41,750,109
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.19
Beneficio por acción (BPA)
-2.08
turnover
14.92M
Beneficio neto
-86.88M

Acerca de Carisma Therapeutics Inc

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.carismatx.com
Sede
Wilmington, Delaware, USA
Fundado
-
Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was US$0.39. Over the last year, Carisma Therapeutics shares have traded in a share price range of US$ 0.3809 to US$ 3.16.

Carisma Therapeutics currently has 41,750,109 shares in issue. The market capitalisation of Carisma Therapeutics is US$16.20 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.19.

CARM Últimas noticias

Más noticias

Form 8-K - Current report

09 Diciembre 2024
Edgar (US Regulatory)

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline PR Newswire PHILADELPHIA, Dec. 9, 2024 Resources realigned to focus primarily on in vivo macrophage engineering...

09 Diciembre 2024
PR Newswire (US)

CARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers

Regulatory News: CARMILA (Paris:CARM) : Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto- détenues) Nombre théorique de droits de...

05 Diciembre 2024
Business Wire

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PR Newswire PHILADELPHIA, Nov. 27, 2024 PHILADELPHIA, Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics...

27 Noviembre 2024
PR Newswire (US)

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 PR Newswire PHILADELPHIA, Nov. 17, 2024...

17 Noviembre 2024
PR Newswire (US)

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR Newswire PHILADELPHIA, Nov. 8, 2024 New findings showcase the potential of in vivo...

08 Noviembre 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Noviembre 2024
Edgar (US Regulatory)

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PHILADELPHIA, Nov. 7, 2024 Initial results from the Phase 1 study of CT-0525, lead...

07 Noviembre 2024
PR Newswire (US)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.0297-6.927921623510.42870.49630.38093460880.43833396CS
4-0.4712-54.14847161570.87020.8880940.38093597540.55058507CS
12-0.5686-58.76395204630.96761.130.38092133480.74232042CS
26-0.621-60.88235294121.021.90.38094901301.24952555CS
52-2.651-86.91803278693.053.160.38093301581.42463888CS
156-5.391-93.10880829025.799.76620.38092919092.86332787CS
260-5.391-93.10880829025.799.76620.38092919092.86332787CS

CARM - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Carisma Therapeutics?
El precio actual de las acciones de Carisma Therapeutics es US$ 0.399
¿Cuántas acciones de Carisma Therapeutics están en circulación?
Carisma Therapeutics tiene 41,750,109 acciones en circulación
¿Cuál es la capitalización de mercado de Carisma Therapeutics?
La capitalización de mercado de Carisma Therapeutics es USD 16.2M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Carisma Therapeutics?
Carisma Therapeutics ha negociado en un rango de US$ 0.3809 a US$ 3.16 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Carisma Therapeutics?
El ratio precio/beneficio de Carisma Therapeutics es -0.19
¿Cuál es el ratio de efectivo a ventas de Carisma Therapeutics?
El ratio de efectivo a ventas de Carisma Therapeutics es 1.12
¿Cuál es la moneda de reporte de Carisma Therapeutics?
Carisma Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Carisma Therapeutics?
El último ingresos anual de Carisma Therapeutics es USD 14.92M
¿Cuál es el último beneficio anual de Carisma Therapeutics?
El último beneficio anual de Carisma Therapeutics es USD -86.88M
¿Cuál es la dirección registrada de Carisma Therapeutics?
La dirección registrada de Carisma Therapeutics es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Carisma Therapeutics?
La dirección del sitio web de Carisma Therapeutics es www.carismatx.com
¿En qué sector industrial opera Carisma Therapeutics?
Carisma Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7.10
(310.40%)
58.74M
HOURHour Loop Inc
US$ 4.40
(207.69%)
97.42M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
CREVCarbon Revolution Public Ltd
US$ 9.16
(135.48%)
26.95M
AVGRAvinger Inc
US$ 1.45
(125.72%)
107.53M
SLGLSol Gel Technologies Ltd
US$ 0.9798
(-40.62%)
3.07M
DRCTDirect Digital Holdings Inc
US$ 3.71
(-32.55%)
23.82M
CHEKCheck Cap Ltd
US$ 1.55
(-31.11%)
3.49M
SYTASiyata Mobile Inc
US$ 0.5178
(-30.83%)
2.63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15.47
(-30.38%)
147.98k
SVMHSRIVARU Holding Ltd
US$ 0.0338
(20.71%)
280.27M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
LITMSnow Lake Resources Ltd
US$ 0.5849
(52.84%)
181.22M
LCIDLucid Group Inc
US$ 3.20
(3.23%)
108.75M
RGTIRigetti Computing Inc
US$ 11.35
(3.56%)
108.38M

CARM Discussion

Ver más
PonkenPlonken PonkenPlonken 3 meses hace
I appreciate you reaching out. I like to follow the money in bioland or predict where it might go. Hence i really like this. Their CAR M CD47 approach is not new and many wished for these trials. The risk however is huge hence no one bit this (monotherapy trial with safety as primary endpoint is almost random)

I am having a very close eye on this as they will share the first clinical data in q4. Any price increase prior might hint at things being right/a rally coming. The problem is, this is monotherapy only and not the one where they combine with the mRNA tech (which is likely where the good stuff is)

So down the road we will be getting some great hints here on whether this might be "THE next big thing" or not.... A LOT of targets nominated by them...
👍️0
jondoeuk jondoeuk 3 meses hace
From this: “Without a doubt there's big biological risk here,” says Carisma CSO Michael Klichinsky. Researchers have yet to prove either the efficacy or the approvability of CAR macrophages. But solid tumours account for 90% of the cancer burden, making the possibility of activity in these settings with an in vivo reprogramming agent all the more appealing. “We’re going after a real unmet need,” he adds. https://www.nature.com/articles/d41573-024-00150-z
👍️0
Prestotic Prestotic 4 meses hace
Vdog, your dog stock shedding another 8.33% today on a pathetic 2 million shares. Going to trips withou a contract soon. Hope you get this message. You could be in Carisma if only you listened.
👍️0
Prestotic Prestotic 4 meses hace
Vdog has no Carisma Therapeutics. Losers like him love losers like VXIT. Carisma up 50 % in 2 weeks, Vxit down 50%. LOVE to say I TOLD YOU SO! How's your DD treating you JA
👍️0
Prestotic Prestotic 4 meses hace
Eat shi* vdog
👍️0
Prestotic Prestotic 4 meses hace
Another 50,000 getting accumulated/ covered @ $1.04. To the moon, soon.
👍️0
Prestotic Prestotic 4 meses hace
No noise here because Carisma is not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid June. Today's action, including buy, buy, buy of 75000 shares at 3:30 pm shows accumulation, or at least some worried shorts covering. Looking for strong move up on phase 2 results.
👍️0
Prestotic Prestotic 4 meses hace
No noise here because Carisma in not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid July. Today's action, including buy, buy, buy of 75000 shares around 2pm shows accumulation, or at least something worried shorts covering. Looking for strong move up on phase 2 results.
👍️0
CancunCharlie CancunCharlie 5 meses hace
Is there anyone here?? No comments in over a month. I think this looks good, but I'm wondering why it's so quite here.
👍️0
PonkenPlonken PonkenPlonken 6 meses hace
pretty strong
nice tech$
👍️0
glenn1919 glenn1919 6 meses hace
CARM.......................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 6 meses hace
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
👍️0
Termite7 Termite7 7 meses hace
Could it be CARM under $0.30 ....???.......Thanks!!!
👍️0
axelvento axelvento 7 meses hace
$1.46 bouncer
👍️0
PonkenPlonken PonkenPlonken 8 meses hace
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00537-x
MRNA provides the tech, 3bln + in biobucks and has not so distant private relative with TOP tier c suite.
👍️0
Monksdream Monksdream 9 meses hace
CARM under $3
👍️0
mrplmer mrplmer 1 año hace
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
mrplmer mrplmer 1 año hace
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
81vette 81vette 1 año hace
1st higher high today and bid growing now,I got some 2.64,will see if dump continues or not
👍️0
81vette 81vette 1 año hace
Yea,distribution only so far today,I am watching for accumulation to start after this dumpathon,short interest went up 300% today also, 100k now,no sign of institutional buying yet,they currently hold 19%
👍️0
stock1ace1 stock1ace1 1 año hace
Red on news .. we no what that means lol
👍️0
81vette 81vette 1 año hace
Deal with Moderna for cancer cures,institutional might buy now lol,went up last time on this news,analysts target $9.50,short 2.45M,not optionable is good,gap filled down now,52 week low 2 weeks ago
👍️0

Su Consulta Reciente

NASDAQ
CARM
Carisma Therapeutics
LSE
55NB
Nordic 46
LSE
17JH
Unilever 27
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados